CCM

Concord Medical Services

CCM

Overview Fund Activity

1 day

5 days

1 month

3 months

6 months

Year to date

1 year

5 years

10 years

About: Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

Employees: 595

Healthcare Medical Care Facilities

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

19,188% more capital invested

Capital invested by funds: $2.06K [Q1] → $398K (+$396K) [Q2]

100% more funds holding

Funds holding: 3 [Q1] → 6 (+3) [Q2]

2.47% more ownership

Funds ownership: 0% [Q1] → 2.47% (+2.47%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

See Fund Rankings

Financial journalist opinion

Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

BEIJING , July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma.

Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

Concord Healthcare Announces Official Release of the Proton Therapy Large Model

BEIJING , May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology.

Concord Healthcare Announces Official Release of the Proton Therapy Large Model

Concord Medical Files Annual Report on Form 20-F for Fiscal 2024

BEIJING , April 25, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.

Concord Medical Files Annual Report on Form 20-F for Fiscal 2024

Concord Medical Announces Result of 2024 Annual General Meeting

BEIJING , Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it held its 2024 annual general meeting of shareholders on December 27, 2024. At the meeting, the shareholders resolved by special resolution that amended and replaced the Fourth Memorandum and Articles of Association of the Company then in effect by the adoption of the Fifth Amended and Restated Memorandum and Articles of Association.

Concord Medical Announces Result of 2024 Annual General Meeting

Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate

BEIJING , Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment (the "Registration Certificate") made by the Company's equipment supplier on December 6, 2024. As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022.

Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate

Concord Medical Schedules 2024 Annual Meeting of Shareholders

BEIJING , Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2024 annual general meeting of shareholders (the "Meeting") on December 27, 2024, at 10:00 a.m. (Beijing Time).

Concord Medical Schedules 2024 Annual Meeting of Shareholders

Concord Medical Reports Financial Results for the First Half of 2024

BEIJING , Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].

Concord Medical Reports Financial Results for the First Half of 2024

Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) announces sample assay results from an additional 2 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Details of the holes are shown in Table 1. Highlights 10.8 grams p.

Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA), announces sample assay results from an additional 26 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Highlights of the gold mineralization that was intersected are s.

Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris

See News Rankings

Charts implemented using Lightweight Charts™